AGILE Digital Twin Demo
This comprehensive view demonstrates how genomic data, clinical history, and research opportunities come together to enable precision medicine at the point of care.
Sarah Johnson
MRN: DEMO-0001Age: 39Date of Birth: 1985-03-15
Pharmacogenomic Profile
Actionable genetic variants affecting medication response and disease risk
CYP2C19
Moderate Impact
Variant: *2/*17
Altered metabolism
Clopidogrel
Omeprazole
Consider alternative antiplatelet therapy
TP53
High Impact
Variant: c.215C>G
Loss of function
Cancer Risk: 45% lifetime risk
Enhanced screening protocol recommended
BRCA2
High Impact
Variant: c.5946delT
Pathogenic
Cancer Risk: 69% breast, 17% ovarian
Discuss prophylactic options